Abstract
Frozen-stored human spleen cells (SC) cultured with streptococcus preparation OK-432 acquired direct cytotoxicity to autologous as well as allogeneic tumor cells. The activated cells started to produce cytocidal cytokine TGIF, which is distinct from previously known cytokines.
We examined the possibility of allogeneic adoptive immunotherapy (AIT) using these OK-432-stimulated spleen cells (OK-SC) in two cancer patients. Rapid necrosis of cancer tissue and remarkable decreases of tumor markers in tumor effusion were observed. There were no severe side effects.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Uchida A, Mickshe M. Lysis of fresh tumor cells by autologous peripheral blood and pleural effusion lymphocytes activated by OK-432. J Natl Cancer Inst 1983; 71: 673–80.
De Ley M, Claeys H. Streptococcal preparation OK-432-induced interferon in human leukocytes: purification and characterization. Int Arch Allergy Appl Immunol 1984; 74: 21–8.
Yamamoto A, Nagamuta M, Usami H, Sugawara Y, Watanabe N, Niitsu Y, Urushizaki I. Release of tumor necrosis factor (TNF) into mouse peritoneal fluid by OK-432, a streptococcal preparation. Immunopharmacology 1986; 11: 79–86.
Katano M, Yamamoto H, Mizoguchi T, Hisatsugu T. Induction of tumor growth inhibitory factor (TGIF) in human mononuclear cells by OK-432, a streptococcal preparation. Cancer Immunol Immunother 1988; 27: 198–204.
Kubota E, Katano M, Kurokawa H, Imamura H, Katsuki T, Yamamoto H, Hisatsugu T, Nagumo F, Tadano J. Tumoricidal effect of human PBMC following stimulation with OK-432 and its application for locoregional immunotherapy in head and neck cancer patients. J Cra-Max-Fac Surg 1993; 1: 30–7.
Katano M, Kubota E, Yamamoto H, Nakamura M, Matsuo T, Hisatsugu T, Katsuki T, Koga H, Ikezaki K, Tabuchi K, Nagumo F, Tadano J. A possible clinical application of multicytokine-producing cytotoxic mononuclear cell (MCCM) therapy. Biotherapy 1991; 3: 373–9.
Herberman RB, Hiserodt J, Vujanovic N. Lymphokine-activated killer cell activity characteristics of effector cells and their progenitors in blood and spleen. Immunol Today 1987; 8: 178–81.
Katz DH, Armeding D. Evidence for the control of lymphocyte interactions by gene products of the I region of the H-2 complex. In: Rosenthal AS, ed. Immune Recognition. New York: Academic Press, 1975: 727–53.
Kubota E, Ishikawa H, Saito K. Modulation of F1 cytotoxic potentials by GvHR: Host- and donor-derived cytotoxic lymphocytes arise in the unirradiated F1 host spleens under the condition of GvHR-associated immunosuppression. J Immunol 1983; 131: 1142–48.
Ishikawa H, Kubota E, Saito K. Modulation of F1 cytotoxic potentials by GvHR: role and mode of action of non-MHC genes that determine the hybrid resistance to GvHR-associated suppression of F1 cytotoxic potential. J Immunol 1984; 132: 2218–25.
Korngold R, Sprent J. Lethal GvHD across minor histocompatibility barriers: Nature of the effector cells and role of the H-2 complex. Immunol Rev 1983; 71: 5–27.
Gleichmann E, Pals ST, Rolink AG, Radaszkiewicz T, Gleichmann H. Graft-versus-host reactions: clues to the etiopathology of a spectrum of immunological diseases. Immunol Today 1984; 5: 324–32.
Weiden PL, Zuckerman N, Hansen JA, Sale GE, Remlinger K, Beck TM, Buckner CD. Fatal graft-versus-host disease in a patient with lymphoblastic leukemia following normal granulocyte transfusions. Blood, 1981; 57: 328–32.
Katano M, Yamamoto H, Kubota E, Nakamura M, Matsuo T, Nagumo F, Hisatsugu T, Katsuki T, Tadano J. The possible use of spleen cells for the adoptive immunotherapy of cancer patients. Surgery Today 1993; 23: 13–20.
Fan J, Kubota E, Imamura H, Shimokama T, Tokunaga O, Katsuki T, Watanabe T. Clear cell odontogenic carcinoma. A case report with massive invasion of neighboring organs and lymph node metastasis. Oral Surg Oral Med Oral Pathol 1992; 74: 768–75.
Koyama Y, Saito T. The criteria of the Japan Society For Cancer Therapy for evaluation of clinical effects of cancer chemotherapy on solid tumors. J Jpn Soc Cancer Ther 1986; 21: 929–53.
Kato H, Torigoe T. Radioimmunoassay for tumor antigen of human cervical squamous cell carcinoma. Cancer 1977; 40: 1621–8.
Gold P, Freedman SO. Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. J Exp Med 1965; 121: 439–45.
Caspersson T, Lomakka G, Zech L. The 24 fluorescence patterns of the human metaphase chromosomes distinguishing characters and variability. Hereditas (Lund) 1971; 67: 89–102.
Katano M, Yamamoto H, Nakamura M, Matsuo T, Hisatsugu T. Synergistic effect of TGIF and interferonγ (IFNγ) on tumor growth. Biotherapy 1990; 2: 33–40.
Kubota E, Katano M, Kurokawa H, Imamura H, Yamamoto H, Katsuki T. Induction of anti-tumor activities in OK-432 stimulated mononuclear cells from human peripheral blood, spleen and bone marrow. BIOTHERAPY 1992; 6; 718–20, summary in English.
Clark EA, Harmon RC. Genetic control of natural cytotoxicity and hybrid resistance. Adv Cancer Res 1980; 31: 227–85.
Sato I, Sato S. Clinical effect of an active cell-mediated immunotherapy against cancer in terminal stage. (Abstr) 13th International Congress of Cancer 1982; p 271.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kubota, E., Katano, M., Imamura, H. et al. Locoregional immunotherapy of head and neck cancers utilizing allogeneic spleen cells — a report of 2 cases. Biotherapy 6, 175–182 (1993). https://doi.org/10.1007/BF01878078
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01878078